LRRKtide

RLGRDKYKTLRQIRQ-acid

  • Description

  • Application Data

Description

Substrate for the leucine-rich repeat kinase 2 (LRRK2), derived from the sequences of the ERM proteins.

See full description

Application Data

Catalogue number crb1000328
Molecular Weight 1930.1
Sequence (one letter code)

RLGRDKYKTLRQIRQ-acid

Sequence (three letter code)

H-Arg-Leu-Gly-Arg-Asp-Lys-Tyr-Lys-Thr-Leu-Arg-Gln-Ile-Arg-Gln-OH

Aliase ERM peptide, ERMtide, Leucine-Rich Repeat Kinase substrate, Moesin
Purity >95%
References

Esteves et al (2014) LRRK2, a puzzling protein: Insights into Parkinson’s disease pathogenesis. Exp. Neurol. 261 206 PMID: 24907399

 

Jaleel et al (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson’s disease mutants affect kinase activity. Biochem. J. 405 (2) 307 PMID: 17447891

Manufactured in: United Kingdom
Data Sheet Material Safety Data Sheet (MSDS)

LRRKtide (also called moesin) is a peptide substrate for leucine-rich repeat kinase 2 (LRRK2). The sequence of LRRKtide has been derived from the ERM proteins: Ezrin (amino acids 561-573), radixin (amino acids 558-570) and moesin (amino acids 539-553). These proteins influence cytoskeletal dynamics by anchoring the cytoskeleton to the plasma membrane. LRRK2 phosphorylates LRRKtide at its Thr558 site.

LRRK2 is a large, ubiquitous protein of unknown function. LRRK2 has GTPase and kinase activity, and is located in multiple areas of the cell where it is found associated with intracellular membranes and vesicular structures. Its multiple cellular locations suggest that LRRK2 may be involved in several cellular pathways. LRRK2 is also found in most organs and mutations in LRRK2 have been identified in Parkinson’s disease.

This peptides has a non-amidated C-terminal end.

LRRKtide

Cat No.Pack SizePriceQty.
1mg£110.00
5mg£320.00
0.5mg£85.00
10mg£550.00
25mg£750.00
Bulk Quote

Download Family PDF

You may also like…